SCOPUS 정보 검색 플랫폼

The Lancet

Volumn 377, Issue 9779, 2011, Pages 1727-1729

Pirfenidone for idiopathic pulmonary fibrosis

(1) Bouros, Demosthenes a

a DEMOCRITUS UNIVERSITY OF THRACE (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WALKING;

EID: 79956356774 PISSN: 01406736 EISSN: 1474547X Source Type: Journal
DOI: 10.1016/S0140-6736(11)60546-1 Document Type: Note

Times cited : (62)

References (12)

1
- 79956341531
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
- 10.1016/S0140-6736(11)60405-4 published online May 14. for the CAPACITY Study Group
- PW Noble, C Albera, WZ Bradford for the CAPACITY Study Group Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 10.1016/S0140-6736(11)60405-4 published online May 14.
- (2011) Lancet
- Noble, P.W.¹ Albera, C.² Bradford, W.Z.³

2
- 79956358690
- S Seymour Division Summary: Overview of the FDA background materials for New Drug Application (NDA) 22-535, Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce the decline in lung function http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM203081.pdf Feb 12, 2010 (accessed May 10, 2010).
- (2010) Division Summary: Overview of the FDA Background Materials for New Drug Application (NDA) 22-535, Esbriet (Pirfenidone) for the Treatment of Patients with Idiopathic Pulmonary Fibrosis (IPF) to Reduce the Decline in Lung Function
- Seymour, S.¹

3
- 0041374155
- Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends
- DOI 10.1164/rccm.200210-1245OC
- PI Latsi, RM du Bois, AG Nicholson Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends Am J Respir Crit Care Med 168 2003 531 537 (Pubitemid 37088594)
- (2003) American Journal of Respiratory and Critical Care Medicine , vol.168 , Issue.5 , pp. 531-537
- Latsi, P.I.¹ Du Bois, R.M.² Nicholson, A.G.³ Colby, T.V.⁴ Bisirtzoglou, D.⁵ Nikolakopoulou, A.⁶ Veeraraghavan, S.⁷ Hansell, D.M.⁸ Wells, A.U.⁹

4
- 79955520497
- Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference
- RM du Bois, D Weycker, C Albera Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference Am J Respir Crit Care Med 183 2010 1231 1237
- (2010) Am J Respir Crit Care Med , vol.183 , pp. 1231-1237
- Du Bois, R.M.¹ Weycker, D.² Albera, C.³

5
- 79952717349
- Idiopathic pulmonary fibrosis: Evidence based guidelines for diagnosis and management. A joint ATS/ERS/JRS/ALAT Statement
- on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
- G Raghu, HR Collard, JJ Egan on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis Idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. A joint ATS/ERS/JRS/ALAT Statement Am J Respir Crit Care Med 183 2011 788 824
- (2011) Am J Respir Crit Care Med , vol.183 , pp. 788-824
- Raghu, G.¹ Collard, H.R.² Egan, J.J.³

6
- 67649195440
- Epidemiology of interstitial lung diseases in Greece
- for the Hellenic Interstitial Lung Diseases Group
- A Karakatsani, D Papakosta, A Rapti for the Hellenic Interstitial Lung Diseases Group Epidemiology of interstitial lung diseases in Greece Respir Med 103 2009 1122 1129
- (2009) Respir Med , vol.103 , pp. 1122-1129
- Karakatsani, A.¹ Papakosta, D.² Rapti, A.³

7
- 20544443765
- The clinical course of patients with idiopathic pulmonary fibrosis
- for the IPF study group
- FJ Martinez, S Safrin, D Weycker for the IPF study group The clinical course of patients with idiopathic pulmonary fibrosis Ann Intern Med 142 2005 963 967
- (2005) Ann Intern Med , vol.142 , pp. 963-967
- Martinez, F.J.¹ Safrin, S.² Weycker, D.³

8
- 26844506715
- Current and future therapeutic approaches in idiopathic pulmonary fibrosis
- DOI 10.1183/09031936.05.00145004
- D Bouros, KM Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur Respir J 26 2005 693 702 (Pubitemid 41448670)
- (2005) European Respiratory Journal , vol.26 , Issue.4 , pp. 693-702
- Bouros, D.¹ Antoniou, K.M.²

9
- 67650355436
- Interferon gamma for idiopathic pulmonary fibrosis
- D Bouros Interferon gamma for idiopathic pulmonary fibrosis Lancet 374 2009 180 182
- (2009) Lancet , vol.374 , pp. 180-182
- Bouros, D.¹

10
- 0032926937
- Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study
- G Raghu, WC Johnson, D Lockhart, Y Mageto Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study Am J Respir Crit Care Med 159 1999 1061 1069 (Pubitemid 29202536)
- (1999) American Journal of Respiratory and Critical Care Medicine , vol.159 , Issue.4 I , pp. 1061-1069
- Raghu, G.¹ Johnson, W.C.² Lockhart, D.³ Mageto, Y.⁴

11
- 77951160564
- Pirfenidone in idiopathic pulmonary fibrosis
- for the Pirfenidone Clinical Study Group in Japan
- H Taniguchi, M Ebina, Y Kondoh for the Pirfenidone Clinical Study Group in Japan Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 35 2010 821 829
- (2010) Eur Respir J , vol.35 , pp. 821-829
- Taniguchi, H.¹ Ebina, M.² Kondoh, Y.³

12
- 77951171086
- Idiopathic pulmonary fibrosis and pirfenidone
- HR Collard Idiopathic pulmonary fibrosis and pirfenidone Eur Respir J 35 2010 728 729
- (2010) Eur Respir J , vol.35 , pp. 728-729
- Collard, H.R.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.